Overview

A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics

Status:
RECRUITING

Trial end date:
2027-01-31

Target enrollment:

Participant gender:

Summary

This study will take place at multiple sites and is divided into three phases:an initial 4-week getting-to-know-you phase,a 26-week main phase where participants receive medication,and a 4-week follow-up phase.Participants will be divided into three groups:two will receive different doses of PEG-rhGH Injection,and the third will receive hGH Injection.The goal is to determine which medication works best.

Phase:

PHASE2

Details

Lead Sponsor:

Changchun GeneScience Pharmaceutical Co., Ltd.

Treatments:

polyethylene glycol-recombinant human growth hormone